MingMed Biotechnology is seeking a Hong Kong listing this year to raise funds to research and market a genetically engineered alternative to Botox in China. The drug developer, based in the Nansha district of Guangzhou, said it would set up an incubation centre in the Hong Kong Science and Technology Park in the third quarter. “Hong Kong has many good universities and research institutes, but it [does not have] a lot of innovative biotech firms,” said MingMed CEO Zhang Yan in an interview on...